About Lantern Pharma
Lantern Pharma Inc. is a publicly-traded, clinical-stage biopharmaceutical company focused on transforming oncology drug development through artificial intelligence and precision medicine. The company operates at the intersection of AI, genomics, and machine learning to deliver targeted cancer therapies to the right patients with significantly reduced development costs and timelines. At the core of Lantern's approach is RADR® (Response Algorithm for Drug Positioning & Rescue), a proprietary AI-powered platform that analyzes over 200 billion oncology-specific data points using more than 200 advanced machine learning algorithms. The platform integrates transcriptome data, genomic data, and drug sensitivity information to predict patient responses, identify biomarkers, and stratify patient populations for clinical trials. This data-driven approach enables the company to rescue and revitalize promising oncology compounds while personalizing cancer treatments. Lantern's current portfolio includes three lead drug candidates and an ADC program spanning 12 cancer indications. The company has one lead product candidate (LP-300) in Phase 2 clinical testing through the Harmonic™ trial for never-smoker patients with non-small cell lung cancer, and Phase 1 programs for LP-184 (advanced solid tumors and glioblastoma) and LP-284 (non-Hodgkin's lymphoma). The company has also developed withZeta.ai, an AI research module that unifies clinical, molecular, and therapeutic information for rare and understudied cancers. Lantern Pharma manages an innovative patent portfolio with 95 issued patents and pending applications across 14 patent families.
Mission & Story
Mission
Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines
Clinical Focus
Medical conditions and clinical areas addressed by Lantern Pharma.
Who It Serves
Milestones & Awards
Recent Milestones
FDA authorization for Harmonic™ Phase 2 trial. August 2024: Announced preliminary patient data showing 86% clinical benefit rate. June 2026 (future date in content): Reported HARMONIC™ data on progression-free survival. Phase 1a enrollment completed for LP-184. Launched withZeta.ai AI research module. RADR® platform exceeded 200 billion data points.
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.